Media relations and tier one placements.
Named reporters at STAT, Endpoints News, Fierce Biotech, GenomeWeb, and The Scientist, plus the business and science desks above them.
The biotech PR agency that signs up to your placement targets and refunds you if we miss
We pitch the science reporters, trade desks, and business editors that investors, partners, and key opinion leaders read before they take your call, then aim that coverage at your search rankings and at the AI answers people now use to build a shortlist. Outlet tiers, placement targets, and dates go in writing before kickoff, behind a 100% guarantee: you get the agreed results or your money back.
The stakes
What a quiet year costs a clinical stage biotech
Most companies shopping for a biotech PR agency are sitting on something real. The mechanism holds. The Phase 1 data is clean.
Two named investigators will say so on the record. Outside a few hundred people in your therapeutic area, nobody has heard of you.
This sector punishes that quietly and expensively. A partner at a crossover fund searches your name before the second meeting and finds a press release from two years ago. A pharma business development lead builds a partnering list out of the companies STAT and Endpoints News keep quoting. A candidate you wanted running clinical operations takes the other offer, because she could not tell from the outside whether you would still exist in three years. None of that appears in a hit report. All of it appears in your next term sheet.
The plate
What our biotech PR agency work covers
Every scope starts from the audience that moves your valuation: investors, partners, key opinion leaders, regulators, patient advocates, or the scientists you are trying to hire.
Data and milestone communications.
IND clearance, first patient dosed, topline Phase 1, 2, and 3 readouts, FDA designations, and peer reviewed publications turned into a story a general assignment reporter can run without mangling the science.
Financing and deal communications.
Series A, B, and C announcements, IPO and follow on visibility, licensing deals, and partnering news timed to how investors actually read them.
Scientific storytelling and message development.
One narrative your chief scientific officer, your chief executive, and your deck all tell the same way.
KOL, analyst, and advocacy engagement.
The independent experts and patient groups a journalist calls to check whether your science is real.
Conference and event PR.
J.P. Morgan Healthcare Conference week, ASCO, AACR, BIO, and the smaller scientific meetings where your buyers already are.
Crisis and issues management.
Clinical holds, safety signals, missed endpoints, and the statement written before the reporter's email lands.
Digital PR, GEO, and measurement.
Earned coverage aimed at the pages that convert, reported against the targets in your scope.
Full menu at public relations services.
The lanes
The subsectors we write for
Gene and cell therapy. Molecular diagnostics. Genomics and proteomics. Synthetic biology. Immunotherapy and oncology. The microbiome. Drug discovery platforms, including the AI companies now selling into them.
Stage matters as much as science. A clinical stage company sells belief to investors and credibility to future partners, so the program runs on data, publications, and the people behind them. A commercial stage company sells a product to payers, prescribers, and health systems, which is a different newsroom and a different story. Diagnostics, tools, and software companies sit between the two.
The embargo
Scrutiny belongs in the scope, not in an apology later
Biotech is where an untrained agency gets expensive fast. You cannot promote an investigational product, and calling an unapproved candidate safe or effective is an FDA problem rather than a copy preference. Journals embargo results, and one leaked quote can cost you the paper. Public companies, and anyone inside an IPO window, answer to disclosure rules, so material news reaches the wire before it reaches a reporter and never the other way around. Results get reported honestly, including the ones that miss, because otherwise the next readout is the one nobody believes.
We write inside those lines by default and build your regulatory, legal, and investor relations review into the timeline rather than treating it as a delay.
The escalation
How the first 90 days run
Week one: targets before tactics.
Discovery with your scientific and commercial leads, a message platform your chief scientific officer will defend in public, a share of voice read against the three companies you get compared to, and a target media list by name. Nothing gets invoiced until the outlet tiers, placement targets, timelines, and deliverables carry your signature.
Weeks two and three: pitching starts.
Named biotech and science reporters, plus expert commentary pitched into the stories already running that week.
Days 30 to 45: first coverage.
Trade and scientific titles land first, because that is where investors, partners, and KOLs read.
Day 90: tier one and an honest review.
National business desks, executive bylines placed, and a line by line read of what landed against what you signed for.
Every month after that looks the same: pitching against the agreed list, a set number of bylines and reactive opportunities, and one report covering placements against target, share of voice, referring domains, branded search, and which AI engines now name you. On our Forbes program the first opportunity usually appears in 4 to 8 weeks, which is a fair read on pace.
AI answers
Getting named when an investor asks AI about your category
Diligence changed. An associate asks ChatGPT, Gemini, or Perplexity which companies are working on a given target or modality, gets six names back, and builds the list from there.
Pharma business development runs a faster version of the same habit. If a model cannot name you, you are not on the list when the list gets made.
An engine names what it can check. That means trade and scientific coverage it already crawls, a pipeline page whose program names, targets, and indications match what the trade press says about you, structured data stating plainly what you are developing and for which indication, and answers on your own site to the questions an associate types out loud. Nobody buys their way into an Endpoints News feature. That is why the pitching and the search work sit on one team here rather than two vendors pointing at each other, and why the same coverage lifts the pages prescribers and patients reach later.
Why AceIt
Why hire AceIt as your biotech PR agency
Count the guarantees on the agency sites ranking above this page. There are none.
The clauserisk sits on our side
Agreed results or your money back- Placement targets, outlet tiers, timelines, deliverables · signed before kickoff
- Not delivered on the timeline we committed to · refunded
A specific journalist's yesnever ours to sell
Every one of them asks a company with a finite runway to commit a five figure monthly retainer and wait.
Biotech makes that gamble worse, because your own calendar hands the agency cover. Nothing landed this quarter? The readout slipped. Nothing to announce? We are between milestones, wait for J.P. Morgan. Eighteen months later the board sees a hit report padded with syndicated reprints, coverage in outlets no investor reads, no lift in branded search, no AI engine naming the company, and a retainer already spent. The agency keeps the fee. You keep the problem, with less runway left to fix it.
So the risk sits on our side instead. You sign off on placement targets, outlet tiers, timelines, and deliverables before kickoff, and if we do not deliver what we committed to, on the timeline we committed to, you get your money back. What we guarantee is the work and those agreed deliverables. We will not sell you a specific journalist's yes, because that decision was never ours to sell. Scoping it that way is what makes the refund real.
Three more differences. Senior people run your account, with no junior manager learning immunology on your budget. Replies land in 1 to 2 hours, which matters most on the day a trial gets paused. And PR, SEO, and web run as one team out of Austin.
Proof
Proof with numbers attached
1M+Brand impressions Vezbi, a community super app, cleared on organic coverage alone while expanding into the U.S.
50+Placements across 12+ industries on the Forbes side, with a first opportunity for most clients within 4 to 8 weeks
4,200+Visits one anonymized client saw off one feature, with a 38% lift in branded search and 12 secondary pickups
DA 94Authority of the backlink that same feature earned
References · clients have been featured in
Vezbi, a community super app, cleared over 1 million brand impressions on organic coverage alone while expanding into the U.S., the Vezbi case study. On the Forbes side: 50+ placements across 12+ industries, a first opportunity for most clients within 4 to 8 weeks, and one anonymized client seeing 4,200+ visits, a 38% lift in branded search, a DA 94 backlink, and 12 secondary pickups off one feature, on the Forbes program. Clients have been featured in Forbes, Bloomberg, TechCrunch, VentureBeat, Wired, Ars Technica, Inc., Fast Company, and USA Today Network.
The number
What biotech PR costs
Every agency on page one for this search hides the number. Six competitor sites, zero prices between them, while the listicles ranking alongside score agencies on exactly that transparency.
We publish ours instead, on the pricing page. A Forbes campaign is priced in writing before kickoff. Run earned media and search together against a 12 month roadmap and you are in mid five figures to six figures a year. Project, retainer, and performance oriented models are all available, and scope and price are settled on the strategy call, in writing, before you commit anything.
The criteria
Who this fits, and who it does not
Inclusion criteriait fits
It fits clinical stage companies with a readout ahead, platform companies that need pharma to grasp what the platform actually does, diagnostics and tools businesses selling to labs and health systems, and funded startups whose next round depends on being known outside their own building.
Exclusion criteriait does not
It does not fit a company that wants STAT promised by Friday, one picking an agency on monthly rate alone, or one whose data would not survive a science reporter reading the supplementary material. If the story is not there yet, you will hear it on the first call. Six months of retainer is an expensive way to reach the same answer.
Questions
Asked before every biotech engagement
Anything else, email [email protected] and it comes back in 1 to 2 hours.
A biotech PR agency earns third party coverage for companies developing therapies, diagnostics, research tools, and platforms. The work covers message development, media relations with science and trade reporters, announcements around IND clearances, data readouts, financings and partnerships, executive and KOL visibility, and crisis response when a trial pauses or a safety signal appears. The point is credibility with investors, partners, regulators, and the scientists you want to hire.
Nobody ranking for this term publishes a number, so the honest answer is that you will sit through a discovery call before anyone quotes you. Ours are published instead. Forbes campaigns are scoped and priced in writing before kickoff, and programs pairing earned media with search run mid five figures to six figures a year. Scope and price go in writing before kickoff, and you get your money back if we miss what we agreed.
Yes, once there is something verifiable to say. Ahead of a financing, coverage sets the narrative investors carry into diligence. Ahead of a partnering conversation, it is how pharma business development finds you at all. It is also often the difference between a senior scientist taking your recruiter's call and ignoring it. What no startup needs is a retainer burning through a year with no milestones in it.
By giving a specific reporter something new, verifiable, and timely. In practice that means a data readout, a regulatory milestone, a financing, a peer reviewed publication, a partnership, or expert commentary on a story already running that week. Coverage follows relationships and timing more than budget: the right beat reporter, pitched before the news breaks, with the science translated and an investigator or KOL available to talk on the record.
PR earns attention, marketing buys it. PR pitches journalists, editors, analysts, and key opinion leaders so independent sources vouch for your science. Marketing runs ads, email, congress booths, and paid social that you control and pay for continuously. In a sector where investors and partners discount anything self published, earned coverage carries more weight, keeps working after the invoice clears, and feeds search rankings and AI answers the way ads never do.
Ask six things. Who runs the account after the pitch. Whether their case studies name a funding round, an outlet, and a date. How they handle embargoes and disclosure rules. How fast they reply. What the program costs. And what happens if they miss. Most firms answer the first five and go quiet on the last one. We agree the targets before kickoff, reply in 1 to 2 hours, and refund you if we do not hit them.
Next step
See the coverage plan before you spend any runway on it
Send us your domain, your next milestone, and the two companies that keep getting quoted instead of you. You get back the story angles we would build, the biotech and science titles we would pitch first, the timeline to first coverage, and the exact numbers we would put in writing. Every engagement carries a 100% guarantee: you get the agreed results or your money back.
Every engagement carries a 100% guarantee: you get the agreed results or your money back